# Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy

> **NCT04652258** · PHASE2 · TERMINATED · sponsor: **University of Zurich** · enrollment: 20 (actual)

## Conditions studied

- Pyrexia

## Interventions

- **DRUG:** Actemra

## Key facts

- **NCT ID:** NCT04652258
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-01
- **Primary completion:** 2021-10-31
- **Final completion:** 2021-10-31
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** too few patients could be included
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04652258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04652258, "Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04652258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*